J INTERN MED: Relationship between calcium channel blockers and survival and ischemic stroke in people with dementia.

The effects of calcium channel blockers (CB) on mortality and ischemic stroke risk in people with dementia are not yet clear.
a recent study published in Journal of Internal Medicine, an authoritative journal in the field of internal medicine, aims to calculate the risk of death and ischemic stroke in people with dementia treated with CCCB and to consider individual drug and dose responses.
researchers conducted a longitudinal cohort study of 18,906 people with hypertension dementia from the Swedish Dementia Registry (SveDem) between 2008 and 2014.
sweden's other registries provide information on mergers, dosing and patient outcomes.
the researchers considered individual CCCB drugs and cumulatively defined daily doses.
compared to non-CCB users, nitrobenzene increased the risk of death in patients with hypertensive dementia (aHR of 1.32; 95% CI of 1.01-1.73; p.lt;0.05).
who were diagnosed with Alzheimer's (AD) or Louis's/Parkinson's disease (DLB-PDD) had a lower mortality rate (aHR of 0.89; 95% CI is 0.80-0.98; p.lt;0.05 and aHR is 0.58; 95% CI is 0.38-0.86, p.lt;0.01), compared to other CCCBs.
alzheimer's patients with Alzheimer's had a lower risk of stroke after taking ammonia chloride (aHR of 0.63; 95% CI of 0.44-0.89; p.lt;0.05).
the researchers used a tendency score matching queue for sensitivity analysis to repeat nitrobenzene (aHR of 1.35; 95% CI of 1.02-1.78; p slt;0.05) and ammonia chlorpyrine in AD (aHR of 0.87; Results in patients with 95% CI of 0.78-0.97; p.lt;0.05) and DLB-PDD (aHR of 0.56, 95% CI of 0.37-0.85; p.lt;0.05).
result, the use of ammonia chloride for dementia patients with AD and DLB-PDD reduces the risk of death.
risk of ischemic stroke in AD patients using ammonia chloride was lower than other CCB users.
.